8-K current report · filed Aug 5, 2026

LivaNova PLC (LIVN) 8-K Current Report: August 5, 2026

Item 2.02Item EX-99.1LIVN overview

Short answer

LivaNova PLC (LIVN) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly results cover the period ended June 30, 2026.

LivaNova PLC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Quarterly results cover the period ended June 30, 2026
  • Earnings press release furnished as Exhibit 99.1, containing the substantive financial details
  • Business update conference call and webcast scheduled for August 5, 2026 at 1 p.m. London time
  • Exhibit 99.1 not deemed filed under Exchange Act Section 18, limiting associated liability and incorporation by reference

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $390.6M, up 10.8% reported and 9.8% constant currency, with Cardiopulmonary and Neuromodulation both growing above 10%
  • Adjusted diluted EPS $1.26 versus $1.05, while adjusted operating margin expanded to 23.2% from 21.9%
  • Full-year constant-currency revenue guidance raised to 8%-9%, adjusted diluted EPS to $4.30-$4.40
  • Adjusted free-cash-flow guidance reduced to $140M-$160M from $160M-$180M for Cardiopulmonary capacity, innovation and IT investments
  • Thermo Fisher supply agreement targets oxygenator component shortages, supporting higher output and improved ability to meet demand

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other LivaNova PLC 8-K filings

Get the next LIVN 8-K as it lands

Follow LIVN for push alerts, or ask the research agent what this filing means.